Plain-English translation of NCT07180992 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Researchers are studying a type of immune cell called monocytes in patients with multiple myeloma who are receiving CAR-T cell therapy (a personalized cancer treatment). The goal is to understand how monocytes behave before and after treatment and whether they can predict which patients will respond well to this therapy.
CAR-T cell therapy has helped many multiple myeloma patients, but some relapse early, and doctors don't yet have reliable ways to predict who will benefit most. This study aims to identify early warning signs or markers that could help doctors predict treatment success and improve care for future patients.
You likely qualify if…
You likely don't qualify if…
You would have blood samples taken before you start CAR-T cell therapy and again after your treatment begins. Researchers will analyze these samples to look at your immune cells and see how they change over time. The study involves only blood draws and medical record review — no additional medications or procedures beyond your standard cancer care.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France
Enrollment target
~25 participants
Started
July 2025
Primary completion
September 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lydia Montes, MD
Centre Hospitalier Universitaire, Amiens
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.